LA
BIOTU

Linden Advisors’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Linden Advisors’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-678,849
Closed -$6.71M – 922
2021
Q1 		$6.71M Buy
+678,849
New +$6.98M 0.05% 240

Other funds holding BIOTU

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Linden Advisors's BIOTU Position: Q2 2021 in Review

Linden Advisors sold out of Biotech Acquisition Company Unit (BIOTU) in Q2 2021, closing a stake of 678,849 shares — an estimated $6.71M sold.

Linden Advisors first reported a position in BIOTU in Q1 2021 and held it in 1 quarter. The position peaked at $6.71M in Q1 2021. 41 funds tracked by Wall St. Rank hold BIOTU as of Q2 2021.

  • Linden Advisors reported no remaining Biotech Acquisition Company Unit position as of Q2 2021 after selling out during the quarter.
  • Linden Advisors sold 678,849 Biotech Acquisition Company Unit shares in Q2 2021, an estimated $6.71M.
  • Linden Advisors first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 1 quarter.
  • Linden Advisors's Biotech Acquisition Company Unit position peaked at $6.71M in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q2 2021.

Based on Linden Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.